1. EJCP Annual Report 2005

   • Rune Dahlqvist
   • Aina Mattsson

   Editorial 22 June 2006 Pages: 493 - 496

   

2. Inhibitory effect of medroxyprogesterone acetate on human liver cytochrome P450 enzymes

   • Jiang-Wei Zhang
   • Yong Liu
   • Ling Yang

   Pharmacokinetics and Disposition 28 April 2006 Pages: 497 - 502

   

3. Montelukast and zafirlukast do not affect the pharmacokinetics of the CYP2C8 substrate pioglitazone

   • Tiina Jaakkola
   • Janne T. Backman
   • Pertti J. Neuvonen

   Pharmacokinetics and Disposition 03 May 2006 Pages: 503 - 509

   

4. Pharmacokinetics and safety of a novel anti-HBs-enriched immunoglobulin in healthy volunteers after subcutaneous and intramuscular administration

   • Petra A. Thürmann
   • Jacek Szymanski
   • C. Sonnenburg

   Pharmacokinetics and Disposition 05 May 2006 Pages: 511 - 512

5. Enantioselective pharmacokinetics of tramadol in CYP2D6 extensive and poor metabolizers

   • Rasmus Steen Pedersen
   • Per Damkier
   • Kim Brøsen

   Pharmacokinetics and Disposition 09 June 2006 Pages: 513 - 521

   

6. Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients

   • Eric Dailly
   • Olivier Tribut
   • Pascale Jolliet

   Pharmacokinetics and Disposition 09 June 2006 Pages: 523 - 526

   

7. Prediction of total propofol clearance based on enzyme activities in microsomes from human kidney and liver

   • Wael S. Al-Jahdari
   • Koujirou Yamamoto
   • Ryuya Horiuchi

   Pharmacokinetics and Disposition 09 June 2006 Pages: 527 - 533

   

8. Influence of carvedilol on serum digoxin levels in heart failure: is there any gender difference?

   • Nezihi Baris
   • Sule Kalkan
   • Hulya Guven

   Pharmacokinetics and Disposition 10 June 2006 Pages: 535 - 538

   

9. Amodiaquine, its desethylated metabolite, or both, inhibit the metabolism of debrisoquine (CYP2D6) and losartan (CYP2C9) in vivo

   • Agneta Wennerholm
   • Anna Nordmark
   • Lars L. Gustafsson

   Pharmacokinetics and Disposition 17 June 2006 Pages: 539 - 546

   

10. Associations between socio-economic factors and the use of prescription medication during pregnancy

    • Charlotte Olesen
    • Nana Thrane
    • Jørn Olsen

    Pharmacoepidemiology and Prescription 04 May 2006 Pages: 547 - 553

11. The use of angiotensin-converting enzyme inhibitors and other drugs with cardiovascular effects by non-demented and demented elderly with a clinical diagnosis of heart failure. A population-based study of the very old

    • Inga Klarin
    • Johan Fastbom
    • Anders Wimo

    Pharmacoepidemiology and Prescription 10 May 2006 Pages: 555 - 562

12. Primary care physicians’ behaviors towards risk of iatrogenesis in elderly patients

    • Bruno Fantino
    • Nicolas Voirin
    • Eric Van Ganse

    Pharmacoepidemiology and Prescription 13 May 2006 Pages: 563 - 570

    

13. Favorable effect on postgraduate clinical practice of a drug-interaction exercise for undergraduate students

    • Shuichi Tsuruoka
    • Atsuhiro Kawaguchi
    • Akio Fujimura

    Pharmacoepidemiology and Prescription 23 May 2006 Pages: 571 - 576

    

14. Narrow and wide prescribers among general practitioners

    • Allan Buusman
    • Jakob Kragstrup
    • Morten Andersen

    Pharmacoepidemiology and Prescription 17 June 2006 Pages: 577 - 583

15. Absence of CYP2B6 promoter −82T>C mutation in Chinese as an additional factor for slow metabolism of drugs commonly used in infections

    • Ming-liang He
    • CK Lin
    • Shui-shan Lee

    Letter to the Editors 13 June 2006 Pages: 585 - 586

16. Effect of tofisopam on the single-oral-dose pharmacokinetics and pharmacodynamics of the cyp3a4 probe drug alprazolam

    • Sándor Drabant
    • Mária Tóth
    • Imre Klebovich

    Letter to the Editors 22 June 2006 Pages: 587 - 588